Xencor falls as royalty dispute with Astra leads to guidance cut
Source: SeekingAlpha
2026-03-05 10:13:32 ET
More on Xencor, AstraZeneca PLC
- AstraZeneca: Q4 Earnings Analysis - Ticks The Boxes, Upgrading To Buy
- AstraZeneca PLC (AZN) Q4 2025 Earnings Call Transcript
- AstraZeneca PLC 2025 Q4 - Results - Earnings Call Presentation
- China drug licensing deals surge nearly 10-fold in value since 2021
- AstraZeneca, Bristol partner with Evinova to use AI in drug development
Read the full article on Seeking Alpha
For further details see:
Xencor falls as royalty dispute with Astra leads to guidance cut
Xencor Inc.
NASDAQ: XNCR
XNCR Trading
1.04% G/L:
$11.62 Last:
256,311 Volume:
$11.72 Open:
XNCR Latest News
XNCR Stock Data
$902,628,328
68,011,331
N/A
68
N/A
Biotechnology & Life Sciences
Healthcare
US
Pasadena
